A5018833620- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Dermatological diseases and infestations
- Infectious Diseases and Mycology
- Advanced Breast Cancer Therapies
- Poxvirus research and outbreaks
- Body Image and Dysmorphia Studies
- Nail Diseases and Treatments
- Eosinophilic Disorders and Syndromes
- Forensic Entomology and Diptera Studies
- Insects and Parasite Interactions
- Tattoo and Body Piercing Complications
- Dermatological and Skeletal Disorders
- Contact Dermatitis and Allergies
- Autoimmune Bullous Skin Diseases
- Beetle Biology and Toxicology Studies
- Cell Image Analysis Techniques
- Cancer Cells and Metastasis
- Cancer, Stress, Anesthesia, and Immune Response
Leiden University Medical Center
2018-2024
Loyola University Medical Center
2024
Massachusetts General Hospital
2020-2023
Alrijne Ziekenhuis
2021
Harvard University
2020
MGH Institute of Health Professions
2020
Worldwide 10-20% of the population is tattooed. However, tattoo complications can occur, such as allergic reactions, infections, and manifestations autoimmune dermatoses. Despite growing popularity tattoos changes in ink composition over last decades, little known about these complications, its clinical aspects, pathomechanism, relative occurrence.The aim this article to describe types aspects dermatological occurrence underlying conditions.We performed a retrospective cohort study enrolling...
: The difference in incidence and severity of anti-PD-1 therapy-related adverse events (irAEs) between adjuvant advanced treated melanoma patients remains unclear, as no head-to-head studies have compared these groups.
Abstract Background Immunotherapy has improved overall survival in metastatic melanoma. Response to therapy can be difficult evaluate as the traditionally used RECIST 1.1 criteria do not capture heterogeneous responses. Here we describe clinical characterization of melanoma patients with a clinically defined mixed response immunotherapy. Methods This was single institution, retrospective analysis stage IV who received first-line anti-CTLA-4, anti-PD1, or combination anti-CTLA-4/anti-PD1....
BackgroundLittle is known about outcomes of adjuvant-treated melanoma patients beyond the clinical trial setting. Since 2019, have been registered in DMTR, a population-based registry to monitor quality and safety care Netherlands. This study aims describe treatment patterns, relapse, toxicity rates setting.MethodsAnalyses were performed on included DMTR. Descriptive statistics used analyse patient-, characteristics. A baseline registration completeness analysis was performed, an eligibility...
A patient with skin of colour presented a 3-month history progressive itch and skin-coloured papules without visible burrows or dermoscopic scabies-features. burrow ink test, however, revealed burrows, confirming clinical diagnosis for scabies. This case underscores the diagnostic utility test scabies in patients darker skin.
Nodular melanoma (NM) is associated with a higher locoregional and distant recurrence rate compared superficial spreading (SSM); it unknown whether the efficacy of systemic therapy limited. Here, we compare immunotherapy BRAF/MEK inhibitors (BRAF/MEKi) in advanced NM to SSM. Patients stage IIIc IV SSM treated anti-CTLA-4 and/or anti-PD-1, or BRAF/MEKi first line, were included from prospective Dutch Melanoma Treatment Registry. The primary objectives metastasis-free survival (DMFS) overall...
A 20-year-old man presented with a 3-month history of itchiness. Papules were seen on the trunk, wrists, and genital area. wrist lesion was covered purple skin marker then wiped alcohol, revealing burrow.
In this study we used total body photography (TBP) to determine whether melanoma emerges from a preexisting naevi or normal-appearing skin in individuals with pathogenic CDKN2a variant. total, 60 cases occurred 44 germline carriers. addition, observed that 78% of the included developed naevi, significantly higher than 30% reported for sporadic melanoma. This high incidence may be due numerous atypical and early bi-allelic loss CDKN2A. Our findings underscore importance routine TBP these...
58 Background: Systemic immune checkpoint blockade therapy anti-PD1 nivolumab combined with anti-CTLA-4 ipilimumab is an effective for metastatic melanoma. The treatment, however, has a high frequency of related adverse events. Interestingly, immune-related events in and anti-CTLA4 monotherapy have been associated improved overall survival Whether correlate enhanced outcomes ipilimumab/nivolumab combination unknown. Methods: Clinical data from patients diagnosed untreated cutaneous stage IV...
Immunotherapy has revolutionized the treatment of metastatic melanoma. Response to therapy can be complex evaluate, as Evaluation Criteria in Solid Tumor (RECIST) does not capture heterogeneous responses. In this retrospective single-institution analysis, we describe management, clinicopathological characteristics, RECIST and disease course melanoma patients with a response first-line anti-CLTA-4 and/or anti-PD-1 between September 2011 2020. 196 patients, 37 had immunotherapy (19%). Distinct...
e21532 Background: The landscape of treatment patients with resectable stage III melanoma has evolved considerably given studies demonstrating survival benefit anti-PD-1 immunotherapy and BRAF/MEK-inhibitor (BRAF/MEKi) therapy in the adjuvant setting, as well surgical changes relating to Multicenter Selective Lymphadenectomy Trial (MSLT)-II trial. Currently, decision treat or BRAF/MEKi setting is dependent upon patient, provider, institutional preferences, but no comparative analysis been...